nodes	percent_of_prediction	percent_of_DWPC	metapath
Rifabutin—CYP1A2—Imiquimod—skin cancer	0.153	0.249	CbGbCtD
Rifabutin—CYP1A2—Vemurafenib—skin cancer	0.0839	0.137	CbGbCtD
Rifabutin—CYP3A4—Temozolomide—skin cancer	0.0802	0.131	CbGbCtD
Rifabutin—CYP3A4—Imiquimod—skin cancer	0.0802	0.131	CbGbCtD
Rifabutin—CYP1A2—Dacarbazine—skin cancer	0.0643	0.105	CbGbCtD
Rifabutin—CYP3A4—Vismodegib—skin cancer	0.0556	0.0906	CbGbCtD
Rifabutin—CYP3A4—Vemurafenib—skin cancer	0.044	0.0716	CbGbCtD
Rifabutin—CYP1A2—Fluorouracil—skin cancer	0.0377	0.0614	CbGbCtD
Rifabutin—HSP90B1—Trafficking and processing of endosomal TLR—TLR7—skin cancer	0.0233	0.253	CbGpPWpGaD
Rifabutin—CYP3A4—Docetaxel—skin cancer	0.0151	0.0246	CbGbCtD
Rifabutin—HSP90B1—hair follicle—skin cancer	0.0104	0.0925	CbGeAlD
Rifabutin—HSP90AA1—endothelium—skin cancer	0.00774	0.0688	CbGeAlD
Rifabutin—HSP90AA1—hair follicle—skin cancer	0.00761	0.0677	CbGeAlD
Rifabutin—HSP90AA1—blood vessel—skin cancer	0.00714	0.0635	CbGeAlD
Rifabutin—HSP90B1—nipple—skin cancer	0.00706	0.0627	CbGeAlD
Rifabutin—HSP90B1—neck—skin cancer	0.00698	0.0621	CbGeAlD
Rifabutin—HSP90B1—IL6-mediated signaling events—MITF—skin cancer	0.00587	0.0637	CbGpPWpGaD
Rifabutin—HSP90AA1—Glucocorticoid receptor regulatory network—KRT17—skin cancer	0.00523	0.0568	CbGpPWpGaD
Rifabutin—HSP90AA1—nipple—skin cancer	0.00516	0.0459	CbGeAlD
Rifabutin—HSP90AA1—neck—skin cancer	0.00511	0.0454	CbGeAlD
Rifabutin—HSP90B1—connective tissue—skin cancer	0.005	0.0445	CbGeAlD
Rifabutin—HSP90B1—epithelium—skin cancer	0.00475	0.0422	CbGeAlD
Rifabutin—HSP90B1—skin of body—skin cancer	0.00452	0.0402	CbGeAlD
Rifabutin—HSP90B1—mammalian vulva—skin cancer	0.00412	0.0366	CbGeAlD
Rifabutin—HSP90AA1—connective tissue—skin cancer	0.00366	0.0325	CbGeAlD
Rifabutin—HSP90B1—lymphoid tissue—skin cancer	0.00366	0.0325	CbGeAlD
Rifabutin—HSP90B1—female reproductive system—skin cancer	0.00353	0.0314	CbGeAlD
Rifabutin—HSP90AA1—epithelium—skin cancer	0.00347	0.0309	CbGeAlD
Rifabutin—HSP90B1—Toll-Like Receptors Cascades—TLR7—skin cancer	0.00346	0.0375	CbGpPWpGaD
Rifabutin—HSP90AA1—skin of body—skin cancer	0.0033	0.0294	CbGeAlD
Rifabutin—HSP90AA1—mammalian vulva—skin cancer	0.00301	0.0268	CbGeAlD
Rifabutin—HSP90AA1—VEGFR1 specific signals—RASA1—skin cancer	0.003	0.0326	CbGpPWpGaD
Rifabutin—HSP90B1—head—skin cancer	0.00295	0.0262	CbGeAlD
Rifabutin—HSP90AA1—Glucocorticoid receptor regulatory network—KRT5—skin cancer	0.00275	0.0298	CbGpPWpGaD
Rifabutin—HSP90AA1—lymphoid tissue—skin cancer	0.00268	0.0238	CbGeAlD
Rifabutin—HSP90AA1—female reproductive system—skin cancer	0.00258	0.023	CbGeAlD
Rifabutin—HSP90AA1—Glucocorticoid receptor regulatory network—KRT14—skin cancer	0.00256	0.0277	CbGpPWpGaD
Rifabutin—Aspartate aminotransferase increased—Vismodegib—skin cancer	0.00236	0.013	CcSEcCtD
Rifabutin—HSP90AA1—Corticotropin-releasing hormone—KRT14—skin cancer	0.00233	0.0253	CbGpPWpGaD
Rifabutin—Lymphopenia—Temozolomide—skin cancer	0.00223	0.0123	CcSEcCtD
Rifabutin—HSP90AA1—head—skin cancer	0.00216	0.0192	CbGeAlD
Rifabutin—HSP90AA1—Class I PI3K signaling events mediated by Akt—FOXO4—skin cancer	0.00212	0.023	CbGpPWpGaD
Rifabutin—HSP90B1—lymph node—skin cancer	0.00206	0.0184	CbGeAlD
Rifabutin—Hepatic enzyme increased—Imiquimod—skin cancer	0.00201	0.0111	CcSEcCtD
Rifabutin—Gastrointestinal symptom NOS—Fluorouracil—skin cancer	0.00179	0.00987	CcSEcCtD
Rifabutin—Connective tissue disorder—Vismodegib—skin cancer	0.00178	0.00985	CcSEcCtD
Rifabutin—Aphasia—Temozolomide—skin cancer	0.00176	0.00971	CcSEcCtD
Rifabutin—CYP1A2—nipple—skin cancer	0.00167	0.0148	CbGeAlD
Rifabutin—HSP90AA1—Hypoxic and oxygen homeostasis regulation of HIF-1-alpha—CDKN2A—skin cancer	0.00158	0.0171	CbGpPWpGaD
Rifabutin—Dysgeusia—Vismodegib—skin cancer	0.00155	0.00854	CcSEcCtD
Rifabutin—HSP90AA1—lymph node—skin cancer	0.00151	0.0134	CbGeAlD
Rifabutin—Lymphopenia—Docetaxel—skin cancer	0.00148	0.00819	CcSEcCtD
Rifabutin—HSP90B1—Metabolism of proteins—EXOC2—skin cancer	0.00141	0.0153	CbGpPWpGaD
Rifabutin—Eosinophilia—Vemurafenib—skin cancer	0.00139	0.00766	CcSEcCtD
Rifabutin—HSP90AA1—IL2 signaling events mediated by PI3K—TERT—skin cancer	0.00135	0.0147	CbGpPWpGaD
Rifabutin—Arthralgia—Vismodegib—skin cancer	0.00135	0.00743	CcSEcCtD
Rifabutin—Myalgia—Vismodegib—skin cancer	0.00135	0.00743	CcSEcCtD
Rifabutin—Unspecified disorder of skin and subcutaneous tissue—Vismodegib—skin cancer	0.00134	0.00738	CcSEcCtD
Rifabutin—Skin disorder—Vismodegib—skin cancer	0.00125	0.00692	CcSEcCtD
Rifabutin—Hepatic enzyme increased—Temozolomide—skin cancer	0.00121	0.00666	CcSEcCtD
Rifabutin—Musculoskeletal discomfort—Vismodegib—skin cancer	0.00118	0.00649	CcSEcCtD
Rifabutin—HSP90AA1—EPH-Ephrin signaling—RASA1—skin cancer	0.00117	0.0127	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling by constitutively active EGFR—NRAS—skin cancer	0.00115	0.0125	CbGpPWpGaD
Rifabutin—Phosphatase alkaline increased—Temozolomide—skin cancer	0.00114	0.0063	CcSEcCtD
Rifabutin—Dyspepsia—Vismodegib—skin cancer	0.00114	0.00627	CcSEcCtD
Rifabutin—Pancytopenia—Imiquimod—skin cancer	0.00114	0.00626	CcSEcCtD
Rifabutin—Decreased appetite—Vismodegib—skin cancer	0.00112	0.00619	CcSEcCtD
Rifabutin—HSP90B1—Innate Immune System—TLR7—skin cancer	0.00112	0.0122	CbGpPWpGaD
Rifabutin—Gastrointestinal disorder—Vismodegib—skin cancer	0.00111	0.00615	CcSEcCtD
Rifabutin—Pain—Vismodegib—skin cancer	0.0011	0.00609	CcSEcCtD
Rifabutin—Connective tissue disorder—Vemurafenib—skin cancer	0.0011	0.00608	CcSEcCtD
Rifabutin—HSP90AA1—VEGFA-VEGFR2 Pathway—RASA1—skin cancer	0.00106	0.0115	CbGpPWpGaD
Rifabutin—Gastrointestinal pain—Vismodegib—skin cancer	0.00106	0.00582	CcSEcCtD
Rifabutin—Eye disorder—Vemurafenib—skin cancer	0.00105	0.00579	CcSEcCtD
Rifabutin—Abdominal pain—Vismodegib—skin cancer	0.00102	0.00563	CcSEcCtD
Rifabutin—Hepatobiliary disease—Imiquimod—skin cancer	0.00101	0.00556	CcSEcCtD
Rifabutin—HSP90B1—IL6-mediated signaling events—IL6—skin cancer	0.000999	0.0108	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling by VEGF—RASA1—skin cancer	0.000998	0.0108	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling by constitutively active EGFR—KRAS—skin cancer	0.000989	0.0107	CbGpPWpGaD
Rifabutin—Dysgeusia—Vemurafenib—skin cancer	0.000957	0.00528	CcSEcCtD
Rifabutin—Blood alkaline phosphatase increased—Temozolomide—skin cancer	0.000953	0.00526	CcSEcCtD
Rifabutin—Connective tissue disorder—Imiquimod—skin cancer	0.00094	0.00519	CcSEcCtD
Rifabutin—Asthenia—Vismodegib—skin cancer	0.000926	0.00511	CcSEcCtD
Rifabutin—Pruritus—Vismodegib—skin cancer	0.000913	0.00504	CcSEcCtD
Rifabutin—Eye disorder—Imiquimod—skin cancer	0.000894	0.00493	CcSEcCtD
Rifabutin—Diarrhoea—Vismodegib—skin cancer	0.000883	0.00487	CcSEcCtD
Rifabutin—HSP90AA1—Hypoxic and oxygen homeostasis regulation of HIF-1-alpha—TP53—skin cancer	0.000879	0.00954	CbGpPWpGaD
Rifabutin—Immune system disorder—Imiquimod—skin cancer	0.000864	0.00477	CcSEcCtD
Rifabutin—Chest discomfort—Docetaxel—skin cancer	0.000858	0.00474	CcSEcCtD
Rifabutin—HSP90AA1—Signaling by constitutively active EGFR—HRAS—skin cancer	0.000841	0.00912	CbGpPWpGaD
Rifabutin—Bronchospasm—Bleomycin—skin cancer	0.000836	0.00461	CcSEcCtD
Rifabutin—HSP90AA1—Regulation of Telomerase—TERT—skin cancer	0.000833	0.00903	CbGpPWpGaD
Rifabutin—Arthralgia—Vemurafenib—skin cancer	0.000832	0.00459	CcSEcCtD
Rifabutin—Myalgia—Vemurafenib—skin cancer	0.000832	0.00459	CcSEcCtD
Rifabutin—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.000826	0.00456	CcSEcCtD
Rifabutin—Aspartate aminotransferase increased—Dactinomycin—skin cancer	0.000825	0.00455	CcSEcCtD
Rifabutin—Vomiting—Vismodegib—skin cancer	0.000821	0.00453	CcSEcCtD
Rifabutin—Rash—Vismodegib—skin cancer	0.000814	0.00449	CcSEcCtD
Rifabutin—Dermatitis—Vismodegib—skin cancer	0.000813	0.00449	CcSEcCtD
Rifabutin—Pancytopenia—Bleomycin—skin cancer	0.000807	0.00445	CcSEcCtD
Rifabutin—Blood bilirubin increased—Docetaxel—skin cancer	0.000803	0.00443	CcSEcCtD
Rifabutin—Skin disorder—Vemurafenib—skin cancer	0.000774	0.00427	CcSEcCtD
Rifabutin—Nausea—Vismodegib—skin cancer	0.000767	0.00423	CcSEcCtD
Rifabutin—Phosphatase alkaline increased—Docetaxel—skin cancer	0.00076	0.00419	CcSEcCtD
Rifabutin—HSP90AA1—Axon guidance—SCN10A—skin cancer	0.000759	0.00823	CbGpPWpGaD
Rifabutin—Pancytopenia—Dactinomycin—skin cancer	0.000752	0.00415	CcSEcCtD
Rifabutin—Aspartate aminotransferase increased—Temozolomide—skin cancer	0.000747	0.00412	CcSEcCtD
Rifabutin—Neutropenia—Dactinomycin—skin cancer	0.000741	0.00409	CcSEcCtD
Rifabutin—HSP90AA1—Validated targets of C-MYC transcriptional activation—TERT—skin cancer	0.000739	0.00801	CbGpPWpGaD
Rifabutin—Alanine aminotransferase increased—Temozolomide—skin cancer	0.000731	0.00403	CcSEcCtD
Rifabutin—HSP90AA1—Aryl Hydrocarbon Receptor—PTGS2—skin cancer	0.000728	0.0079	CbGpPWpGaD
Rifabutin—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.000726	0.00401	CcSEcCtD
Rifabutin—Convulsion—Imiquimod—skin cancer	0.000722	0.00398	CcSEcCtD
Rifabutin—Myalgia—Imiquimod—skin cancer	0.000709	0.00391	CcSEcCtD
Rifabutin—Chest pain—Imiquimod—skin cancer	0.000709	0.00391	CcSEcCtD
Rifabutin—Arthralgia—Imiquimod—skin cancer	0.000709	0.00391	CcSEcCtD
Rifabutin—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.000704	0.00389	CcSEcCtD
Rifabutin—Decreased appetite—Vemurafenib—skin cancer	0.000693	0.00382	CcSEcCtD
Rifabutin—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000688	0.0038	CcSEcCtD
Rifabutin—Pancytopenia—Temozolomide—skin cancer	0.00068	0.00375	CcSEcCtD
Rifabutin—Neutropenia—Temozolomide—skin cancer	0.00067	0.0037	CcSEcCtD
Rifabutin—Shock—Imiquimod—skin cancer	0.000669	0.00369	CcSEcCtD
Rifabutin—HSP90AA1—Validated targets of C-MYC transcriptional activation—CDK4—skin cancer	0.000661	0.00717	CbGpPWpGaD
Rifabutin—Skin disorder—Imiquimod—skin cancer	0.00066	0.00364	CcSEcCtD
Rifabutin—HSP90AA1—Signaling events mediated by VEGFR1 and VEGFR2—BRAF—skin cancer	0.000659	0.00715	CbGpPWpGaD
Rifabutin—Agranulocytosis—Dactinomycin—skin cancer	0.000659	0.00364	CcSEcCtD
Rifabutin—Eosinophilia—Fluorouracil—skin cancer	0.000654	0.00361	CcSEcCtD
Rifabutin—HSP90B1—Immune System—TLR7—skin cancer	0.000653	0.00708	CbGpPWpGaD
Rifabutin—Anorexia—Imiquimod—skin cancer	0.000648	0.00358	CcSEcCtD
Rifabutin—Hepatitis—Dactinomycin—skin cancer	0.000634	0.0035	CcSEcCtD
Rifabutin—Blood alkaline phosphatase increased—Docetaxel—skin cancer	0.000634	0.0035	CcSEcCtD
Rifabutin—Body temperature increased—Vemurafenib—skin cancer	0.00063	0.00348	CcSEcCtD
Rifabutin—Pancytopenia—Fluorouracil—skin cancer	0.000627	0.00346	CcSEcCtD
Rifabutin—Musculoskeletal discomfort—Imiquimod—skin cancer	0.000619	0.00342	CcSEcCtD
Rifabutin—HSP90AA1—Signaling by ERBB2—FOXO4—skin cancer	0.000619	0.00672	CbGpPWpGaD
Rifabutin—Insomnia—Imiquimod—skin cancer	0.000615	0.00339	CcSEcCtD
Rifabutin—Paraesthesia—Imiquimod—skin cancer	0.000611	0.00337	CcSEcCtD
Rifabutin—Dyspnoea—Imiquimod—skin cancer	0.000606	0.00334	CcSEcCtD
Rifabutin—Hepatobiliary disease—Temozolomide—skin cancer	0.000604	0.00333	CcSEcCtD
Rifabutin—CYP3A4—female reproductive system—skin cancer	0.000604	0.00537	CbGeAlD
Rifabutin—Dyspepsia—Imiquimod—skin cancer	0.000599	0.0033	CcSEcCtD
Rifabutin—Decreased appetite—Imiquimod—skin cancer	0.000591	0.00326	CcSEcCtD
Rifabutin—Hypersensitivity—Vemurafenib—skin cancer	0.000587	0.00324	CcSEcCtD
Rifabutin—Gastrointestinal disorder—Imiquimod—skin cancer	0.000587	0.00324	CcSEcCtD
Rifabutin—Pain—Imiquimod—skin cancer	0.000581	0.00321	CcSEcCtD
Rifabutin—HSP90B1—Innate Immune System—FOXO4—skin cancer	0.000577	0.00626	CbGpPWpGaD
Rifabutin—HSP90AA1—Class I PI3K signaling events—NRAS—skin cancer	0.000577	0.00625	CbGpPWpGaD
Rifabutin—Hepatitis—Temozolomide—skin cancer	0.000574	0.00316	CcSEcCtD
Rifabutin—Asthenia—Vemurafenib—skin cancer	0.000572	0.00316	CcSEcCtD
Rifabutin—HSP90AA1—Signaling by EGFR in Cancer—FOXO4—skin cancer	0.00057	0.00618	CbGpPWpGaD
Rifabutin—HSP90AA1—Aryl Hydrocarbon Receptor—NRAS—skin cancer	0.000567	0.00615	CbGpPWpGaD
Rifabutin—Pruritus—Vemurafenib—skin cancer	0.000564	0.00311	CcSEcCtD
Rifabutin—Connective tissue disorder—Temozolomide—skin cancer	0.000564	0.00311	CcSEcCtD
Rifabutin—Feeling abnormal—Imiquimod—skin cancer	0.00056	0.00309	CcSEcCtD
Rifabutin—Gastrointestinal pain—Imiquimod—skin cancer	0.000556	0.00307	CcSEcCtD
Rifabutin—Agranulocytosis—Fluorouracil—skin cancer	0.000549	0.00303	CcSEcCtD
Rifabutin—Anaemia—Bleomycin—skin cancer	0.000547	0.00302	CcSEcCtD
Rifabutin—Diarrhoea—Vemurafenib—skin cancer	0.000546	0.00301	CcSEcCtD
Rifabutin—HSP90AA1—Developmental Biology—SCN10A—skin cancer	0.000541	0.00587	CbGpPWpGaD
Rifabutin—Abdominal pain—Imiquimod—skin cancer	0.000537	0.00297	CcSEcCtD
Rifabutin—Body temperature increased—Imiquimod—skin cancer	0.000537	0.00297	CcSEcCtD
Rifabutin—Eye disorder—Temozolomide—skin cancer	0.000536	0.00296	CcSEcCtD
Rifabutin—Leukopenia—Bleomycin—skin cancer	0.00053	0.00292	CcSEcCtD
Rifabutin—Immune system disorder—Temozolomide—skin cancer	0.000518	0.00286	CcSEcCtD
Rifabutin—HSP90AA1—Corticotropin-releasing hormone—BRAF—skin cancer	0.000518	0.00562	CbGpPWpGaD
Rifabutin—Anaemia—Dactinomycin—skin cancer	0.00051	0.00281	CcSEcCtD
Rifabutin—Vomiting—Vemurafenib—skin cancer	0.000507	0.0028	CcSEcCtD
Rifabutin—Myalgia—Bleomycin—skin cancer	0.000504	0.00278	CcSEcCtD
Rifabutin—Chest pain—Bleomycin—skin cancer	0.000504	0.00278	CcSEcCtD
Rifabutin—Rash—Vemurafenib—skin cancer	0.000503	0.00277	CcSEcCtD
Rifabutin—Dermatitis—Vemurafenib—skin cancer	0.000502	0.00277	CcSEcCtD
Rifabutin—Hypersensitivity—Imiquimod—skin cancer	0.000501	0.00276	CcSEcCtD
Rifabutin—Headache—Vemurafenib—skin cancer	0.000499	0.00276	CcSEcCtD
Rifabutin—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.000496	0.00274	CcSEcCtD
Rifabutin—HSP90AA1—Class I PI3K signaling events—KRAS—skin cancer	0.000496	0.00538	CbGpPWpGaD
Rifabutin—Leukopenia—Dactinomycin—skin cancer	0.000494	0.00273	CcSEcCtD
Rifabutin—Dysgeusia—Temozolomide—skin cancer	0.000489	0.0027	CcSEcCtD
Rifabutin—Asthenia—Imiquimod—skin cancer	0.000488	0.00269	CcSEcCtD
Rifabutin—HSP90AA1—Aryl Hydrocarbon Receptor—KRAS—skin cancer	0.000488	0.00529	CbGpPWpGaD
Rifabutin—Confusional state—Bleomycin—skin cancer	0.000487	0.00269	CcSEcCtD
Rifabutin—Alanine aminotransferase increased—Docetaxel—skin cancer	0.000486	0.00268	CcSEcCtD
Rifabutin—Pruritus—Imiquimod—skin cancer	0.000481	0.00265	CcSEcCtD
Rifabutin—Nausea—Vemurafenib—skin cancer	0.000474	0.00261	CcSEcCtD
Rifabutin—Thrombocytopenia—Bleomycin—skin cancer	0.000473	0.00261	CcSEcCtD
Rifabutin—Myalgia—Dactinomycin—skin cancer	0.00047	0.00259	CcSEcCtD
Rifabutin—Bronchospasm—Docetaxel—skin cancer	0.000469	0.00259	CcSEcCtD
Rifabutin—Diarrhoea—Imiquimod—skin cancer	0.000465	0.00257	CcSEcCtD
Rifabutin—Anaemia—Temozolomide—skin cancer	0.000461	0.00255	CcSEcCtD
Rifabutin—Anorexia—Bleomycin—skin cancer	0.00046	0.00254	CcSEcCtD
Rifabutin—HSP90AA1—LKB1 signaling events—TP53—skin cancer	0.000457	0.00496	CbGpPWpGaD
Rifabutin—Pancytopenia—Docetaxel—skin cancer	0.000453	0.0025	CcSEcCtD
Rifabutin—Leukopenia—Temozolomide—skin cancer	0.000447	0.00247	CcSEcCtD
Rifabutin—Neutropenia—Docetaxel—skin cancer	0.000446	0.00246	CcSEcCtD
Rifabutin—Thrombocytopenia—Dactinomycin—skin cancer	0.000441	0.00243	CcSEcCtD
Rifabutin—Musculoskeletal discomfort—Bleomycin—skin cancer	0.00044	0.00243	CcSEcCtD
Rifabutin—HSP90AA1—Innate Immune System—TLR7—skin cancer	0.000437	0.00474	CbGpPWpGaD
Rifabutin—HSP90AA1—Axon guidance—RASA1—skin cancer	0.000436	0.00473	CbGpPWpGaD
Rifabutin—Paraesthesia—Bleomycin—skin cancer	0.000434	0.00239	CcSEcCtD
Rifabutin—Convulsion—Temozolomide—skin cancer	0.000433	0.00239	CcSEcCtD
Rifabutin—Vomiting—Imiquimod—skin cancer	0.000432	0.00239	CcSEcCtD
Rifabutin—Dyspnoea—Bleomycin—skin cancer	0.000431	0.00238	CcSEcCtD
Rifabutin—Anorexia—Dactinomycin—skin cancer	0.000429	0.00237	CcSEcCtD
Rifabutin—Rash—Imiquimod—skin cancer	0.000429	0.00237	CcSEcCtD
Rifabutin—Dermatitis—Imiquimod—skin cancer	0.000428	0.00236	CcSEcCtD
Rifabutin—Headache—Imiquimod—skin cancer	0.000426	0.00235	CcSEcCtD
Rifabutin—Anaemia—Fluorouracil—skin cancer	0.000425	0.00235	CcSEcCtD
Rifabutin—Arthralgia—Temozolomide—skin cancer	0.000425	0.00235	CcSEcCtD
Rifabutin—Myalgia—Temozolomide—skin cancer	0.000425	0.00235	CcSEcCtD
Rifabutin—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000422	0.00233	CcSEcCtD
Rifabutin—HSP90AA1—Class I PI3K signaling events—HRAS—skin cancer	0.000422	0.00458	CbGpPWpGaD
Rifabutin—Decreased appetite—Bleomycin—skin cancer	0.00042	0.00232	CcSEcCtD
Rifabutin—HSP90B1—Toll-Like Receptors Cascades—IL6—skin cancer	0.000415	0.0045	CbGpPWpGaD
Rifabutin—HSP90AA1—Aryl Hydrocarbon Receptor—HRAS—skin cancer	0.000414	0.0045	CbGpPWpGaD
Rifabutin—Jaundice—Docetaxel—skin cancer	0.000414	0.00228	CcSEcCtD
Rifabutin—HSP90AA1—Signaling Pathways—RHOU—skin cancer	0.000414	0.00449	CbGpPWpGaD
Rifabutin—Pain—Bleomycin—skin cancer	0.000413	0.00228	CcSEcCtD
Rifabutin—Leukopenia—Fluorouracil—skin cancer	0.000412	0.00227	CcSEcCtD
Rifabutin—Confusional state—Temozolomide—skin cancer	0.000411	0.00227	CcSEcCtD
Rifabutin—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.00041	0.00226	CcSEcCtD
Rifabutin—Nausea—Imiquimod—skin cancer	0.000404	0.00223	CcSEcCtD
Rifabutin—Hepatobiliary disease—Docetaxel—skin cancer	0.000402	0.00222	CcSEcCtD
Rifabutin—Thrombocytopenia—Temozolomide—skin cancer	0.000399	0.0022	CcSEcCtD
Rifabutin—Convulsion—Fluorouracil—skin cancer	0.000399	0.0022	CcSEcCtD
Rifabutin—Feeling abnormal—Bleomycin—skin cancer	0.000398	0.0022	CcSEcCtD
Rifabutin—Agranulocytosis—Docetaxel—skin cancer	0.000396	0.00219	CcSEcCtD
Rifabutin—Skin disorder—Temozolomide—skin cancer	0.000396	0.00218	CcSEcCtD
Rifabutin—Chest pain—Fluorouracil—skin cancer	0.000392	0.00216	CcSEcCtD
Rifabutin—Myalgia—Fluorouracil—skin cancer	0.000392	0.00216	CcSEcCtD
Rifabutin—Decreased appetite—Dactinomycin—skin cancer	0.000392	0.00216	CcSEcCtD
Rifabutin—Anorexia—Temozolomide—skin cancer	0.000388	0.00214	CcSEcCtD
Rifabutin—Pain—Dactinomycin—skin cancer	0.000385	0.00213	CcSEcCtD
Rifabutin—HSP90B1—SIDS Susceptibility Pathways—IL6—skin cancer	0.000382	0.00415	CbGpPWpGaD
Rifabutin—Body temperature increased—Bleomycin—skin cancer	0.000382	0.00211	CcSEcCtD
Rifabutin—Hepatitis—Docetaxel—skin cancer	0.000381	0.0021	CcSEcCtD
Rifabutin—Confusional state—Fluorouracil—skin cancer	0.000379	0.00209	CcSEcCtD
Rifabutin—Connective tissue disorder—Docetaxel—skin cancer	0.000375	0.00207	CcSEcCtD
Rifabutin—Feeling abnormal—Dactinomycin—skin cancer	0.000371	0.00205	CcSEcCtD
Rifabutin—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000371	0.00205	CcSEcCtD
Rifabutin—Insomnia—Temozolomide—skin cancer	0.000369	0.00203	CcSEcCtD
Rifabutin—Gastrointestinal pain—Dactinomycin—skin cancer	0.000368	0.00203	CcSEcCtD
Rifabutin—Thrombocytopenia—Fluorouracil—skin cancer	0.000368	0.00203	CcSEcCtD
Rifabutin—Paraesthesia—Temozolomide—skin cancer	0.000366	0.00202	CcSEcCtD
Rifabutin—Dyspnoea—Temozolomide—skin cancer	0.000363	0.002	CcSEcCtD
Rifabutin—Dyspepsia—Temozolomide—skin cancer	0.000359	0.00198	CcSEcCtD
Rifabutin—Anorexia—Fluorouracil—skin cancer	0.000358	0.00197	CcSEcCtD
Rifabutin—Eye disorder—Docetaxel—skin cancer	0.000356	0.00197	CcSEcCtD
Rifabutin—Body temperature increased—Dactinomycin—skin cancer	0.000356	0.00196	CcSEcCtD
Rifabutin—Abdominal pain—Dactinomycin—skin cancer	0.000356	0.00196	CcSEcCtD
Rifabutin—Hypersensitivity—Bleomycin—skin cancer	0.000356	0.00196	CcSEcCtD
Rifabutin—Decreased appetite—Temozolomide—skin cancer	0.000354	0.00195	CcSEcCtD
Rifabutin—Gastrointestinal disorder—Temozolomide—skin cancer	0.000352	0.00194	CcSEcCtD
Rifabutin—Pain—Temozolomide—skin cancer	0.000348	0.00192	CcSEcCtD
Rifabutin—Asthenia—Bleomycin—skin cancer	0.000347	0.00191	CcSEcCtD
Rifabutin—Immune system disorder—Docetaxel—skin cancer	0.000344	0.0019	CcSEcCtD
Rifabutin—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000342	0.00189	CcSEcCtD
Rifabutin—Pruritus—Bleomycin—skin cancer	0.000342	0.00189	CcSEcCtD
Rifabutin—Insomnia—Fluorouracil—skin cancer	0.00034	0.00187	CcSEcCtD
Rifabutin—Paraesthesia—Fluorouracil—skin cancer	0.000337	0.00186	CcSEcCtD
Rifabutin—HSP90B1—Immune System—FOXO4—skin cancer	0.000336	0.00365	CbGpPWpGaD
Rifabutin—Feeling abnormal—Temozolomide—skin cancer	0.000336	0.00185	CcSEcCtD
Rifabutin—Dyspnoea—Fluorouracil—skin cancer	0.000335	0.00185	CcSEcCtD
Rifabutin—Gastrointestinal pain—Temozolomide—skin cancer	0.000333	0.00184	CcSEcCtD
Rifabutin—Hypersensitivity—Dactinomycin—skin cancer	0.000332	0.00183	CcSEcCtD
Rifabutin—Dyspepsia—Fluorouracil—skin cancer	0.00033	0.00182	CcSEcCtD
Rifabutin—Decreased appetite—Fluorouracil—skin cancer	0.000326	0.0018	CcSEcCtD
Rifabutin—HSP90AA1—TNF alpha Signaling Pathway—NRAS—skin cancer	0.000325	0.00353	CbGpPWpGaD
Rifabutin—Dysgeusia—Docetaxel—skin cancer	0.000325	0.00179	CcSEcCtD
Rifabutin—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000324	0.00179	CcSEcCtD
Rifabutin—Asthenia—Dactinomycin—skin cancer	0.000323	0.00178	CcSEcCtD
Rifabutin—Body temperature increased—Temozolomide—skin cancer	0.000322	0.00178	CcSEcCtD
Rifabutin—Abdominal pain—Temozolomide—skin cancer	0.000322	0.00178	CcSEcCtD
Rifabutin—Pain—Fluorouracil—skin cancer	0.000321	0.00177	CcSEcCtD
Rifabutin—HSP90AA1—Developmental Biology—RASA1—skin cancer	0.000311	0.00337	CbGpPWpGaD
Rifabutin—Feeling abnormal—Fluorouracil—skin cancer	0.000309	0.00171	CcSEcCtD
Rifabutin—Diarrhoea—Dactinomycin—skin cancer	0.000308	0.0017	CcSEcCtD
Rifabutin—Vomiting—Bleomycin—skin cancer	0.000307	0.00169	CcSEcCtD
Rifabutin—Anaemia—Docetaxel—skin cancer	0.000307	0.00169	CcSEcCtD
Rifabutin—Rash—Bleomycin—skin cancer	0.000305	0.00168	CcSEcCtD
Rifabutin—Dermatitis—Bleomycin—skin cancer	0.000304	0.00168	CcSEcCtD
Rifabutin—Hypersensitivity—Temozolomide—skin cancer	0.0003	0.00166	CcSEcCtD
Rifabutin—Leukopenia—Docetaxel—skin cancer	0.000297	0.00164	CcSEcCtD
Rifabutin—Body temperature increased—Fluorouracil—skin cancer	0.000297	0.00164	CcSEcCtD
Rifabutin—Asthenia—Temozolomide—skin cancer	0.000292	0.00161	CcSEcCtD
Rifabutin—HSP90AA1—VEGFA-VEGFR2 Pathway—NRAS—skin cancer	0.000288	0.00313	CbGpPWpGaD
Rifabutin—Pruritus—Temozolomide—skin cancer	0.000288	0.00159	CcSEcCtD
Rifabutin—Convulsion—Docetaxel—skin cancer	0.000288	0.00159	CcSEcCtD
Rifabutin—Nausea—Bleomycin—skin cancer	0.000287	0.00158	CcSEcCtD
Rifabutin—Vomiting—Dactinomycin—skin cancer	0.000286	0.00158	CcSEcCtD
Rifabutin—Rash—Dactinomycin—skin cancer	0.000284	0.00157	CcSEcCtD
Rifabutin—Chest pain—Docetaxel—skin cancer	0.000283	0.00156	CcSEcCtD
Rifabutin—Myalgia—Docetaxel—skin cancer	0.000283	0.00156	CcSEcCtD
Rifabutin—Arthralgia—Docetaxel—skin cancer	0.000283	0.00156	CcSEcCtD
Rifabutin—HSP90AA1—Validated targets of C-MYC transcriptional activation—TP53—skin cancer	0.000281	0.00305	CbGpPWpGaD
Rifabutin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000281	0.00155	CcSEcCtD
Rifabutin—HSP90AA1—TNF alpha Signaling Pathway—KRAS—skin cancer	0.00028	0.00304	CbGpPWpGaD
Rifabutin—Diarrhoea—Temozolomide—skin cancer	0.000279	0.00154	CcSEcCtD
Rifabutin—HSP90AA1—Cell Cycle—MLH1—skin cancer	0.000278	0.00301	CbGpPWpGaD
Rifabutin—Hypersensitivity—Fluorouracil—skin cancer	0.000277	0.00153	CcSEcCtD
Rifabutin—Confusional state—Docetaxel—skin cancer	0.000273	0.00151	CcSEcCtD
Rifabutin—HSP90AA1—Glucocorticoid receptor regulatory network—TP53—skin cancer	0.000273	0.00296	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling by VEGF—NRAS—skin cancer	0.000272	0.00295	CbGpPWpGaD
Rifabutin—Nausea—Dactinomycin—skin cancer	0.000268	0.00148	CcSEcCtD
Rifabutin—Shock—Docetaxel—skin cancer	0.000267	0.00147	CcSEcCtD
Rifabutin—Pruritus—Fluorouracil—skin cancer	0.000266	0.00147	CcSEcCtD
Rifabutin—Thrombocytopenia—Docetaxel—skin cancer	0.000265	0.00146	CcSEcCtD
Rifabutin—Skin disorder—Docetaxel—skin cancer	0.000263	0.00145	CcSEcCtD
Rifabutin—Vomiting—Temozolomide—skin cancer	0.000259	0.00143	CcSEcCtD
Rifabutin—Anorexia—Docetaxel—skin cancer	0.000258	0.00143	CcSEcCtD
Rifabutin—Rash—Temozolomide—skin cancer	0.000257	0.00142	CcSEcCtD
Rifabutin—Diarrhoea—Fluorouracil—skin cancer	0.000257	0.00142	CcSEcCtD
Rifabutin—Dermatitis—Temozolomide—skin cancer	0.000257	0.00142	CcSEcCtD
Rifabutin—Headache—Temozolomide—skin cancer	0.000255	0.00141	CcSEcCtD
Rifabutin—HSP90AA1—Immune System—TLR7—skin cancer	0.000255	0.00276	CbGpPWpGaD
Rifabutin—HSP90AA1—Cellular responses to stress—CDK4—skin cancer	0.000252	0.00273	CbGpPWpGaD
Rifabutin—HSP90AA1—Glucocorticoid receptor regulatory network—IL6—skin cancer	0.00025	0.00271	CbGpPWpGaD
Rifabutin—HSP90AA1—VEGFA-VEGFR2 Pathway—KRAS—skin cancer	0.000248	0.00269	CbGpPWpGaD
Rifabutin—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000247	0.00136	CcSEcCtD
Rifabutin—Insomnia—Docetaxel—skin cancer	0.000245	0.00135	CcSEcCtD
Rifabutin—Paraesthesia—Docetaxel—skin cancer	0.000243	0.00134	CcSEcCtD
Rifabutin—Nausea—Temozolomide—skin cancer	0.000242	0.00134	CcSEcCtD
Rifabutin—Dyspnoea—Docetaxel—skin cancer	0.000242	0.00133	CcSEcCtD
Rifabutin—Vomiting—Fluorouracil—skin cancer	0.000239	0.00132	CcSEcCtD
Rifabutin—Dyspepsia—Docetaxel—skin cancer	0.000239	0.00132	CcSEcCtD
Rifabutin—HSP90AA1—TNF alpha Signaling Pathway—HRAS—skin cancer	0.000238	0.00258	CbGpPWpGaD
Rifabutin—Rash—Fluorouracil—skin cancer	0.000237	0.00131	CcSEcCtD
Rifabutin—Dermatitis—Fluorouracil—skin cancer	0.000236	0.0013	CcSEcCtD
Rifabutin—Decreased appetite—Docetaxel—skin cancer	0.000236	0.0013	CcSEcCtD
Rifabutin—Headache—Fluorouracil—skin cancer	0.000235	0.0013	CcSEcCtD
Rifabutin—HSP90AA1—Signaling by VEGF—KRAS—skin cancer	0.000234	0.00254	CbGpPWpGaD
Rifabutin—HSP90AA1—EPH-Ephrin signaling—HRAS—skin cancer	0.000234	0.00254	CbGpPWpGaD
Rifabutin—Gastrointestinal disorder—Docetaxel—skin cancer	0.000234	0.00129	CcSEcCtD
Rifabutin—Pain—Docetaxel—skin cancer	0.000232	0.00128	CcSEcCtD
Rifabutin—HSP90AA1—TNF alpha Signaling Pathway—IL6—skin cancer	0.000228	0.00247	CbGpPWpGaD
Rifabutin—HSP90AA1—Metabolism—PLIN2—skin cancer	0.000227	0.00246	CbGpPWpGaD
Rifabutin—HSP90AA1—Innate Immune System—FOXO4—skin cancer	0.000225	0.00244	CbGpPWpGaD
Rifabutin—Feeling abnormal—Docetaxel—skin cancer	0.000223	0.00123	CcSEcCtD
Rifabutin—Nausea—Fluorouracil—skin cancer	0.000223	0.00123	CcSEcCtD
Rifabutin—Gastrointestinal pain—Docetaxel—skin cancer	0.000222	0.00122	CcSEcCtD
Rifabutin—HSP90AA1—Disease—CSPG4—skin cancer	0.000219	0.00237	CbGpPWpGaD
Rifabutin—Abdominal pain—Docetaxel—skin cancer	0.000214	0.00118	CcSEcCtD
Rifabutin—Body temperature increased—Docetaxel—skin cancer	0.000214	0.00118	CcSEcCtD
Rifabutin—HSP90AA1—VEGFA-VEGFR2 Pathway—HRAS—skin cancer	0.000211	0.00229	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling by ERBB2—NRAS—skin cancer	0.000206	0.00223	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling Pathways—PTCH2—skin cancer	0.000202	0.00219	CbGpPWpGaD
Rifabutin—HSP90AA1—VEGFA-VEGFR2 Pathway—IL6—skin cancer	0.000202	0.00219	CbGpPWpGaD
Rifabutin—Hypersensitivity—Docetaxel—skin cancer	0.0002	0.0011	CcSEcCtD
Rifabutin—HSP90AA1—Signaling by VEGF—HRAS—skin cancer	0.000199	0.00216	CbGpPWpGaD
Rifabutin—Asthenia—Docetaxel—skin cancer	0.000194	0.00107	CcSEcCtD
Rifabutin—HSP90AA1—Cellular responses to stress—CDKN2A—skin cancer	0.000192	0.00209	CbGpPWpGaD
Rifabutin—HSP90B1—Innate Immune System—NRAS—skin cancer	0.000192	0.00208	CbGpPWpGaD
Rifabutin—Pruritus—Docetaxel—skin cancer	0.000192	0.00106	CcSEcCtD
Rifabutin—HSP90AA1—Signaling by VEGF—IL6—skin cancer	0.000191	0.00207	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling by EGFR in Cancer—NRAS—skin cancer	0.000189	0.00205	CbGpPWpGaD
Rifabutin—Diarrhoea—Docetaxel—skin cancer	0.000185	0.00102	CcSEcCtD
Rifabutin—HSP90AA1—Metabolism—CSPG4—skin cancer	0.000183	0.00199	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling by ERBB2—KRAS—skin cancer	0.000177	0.00192	CbGpPWpGaD
Rifabutin—Vomiting—Docetaxel—skin cancer	0.000172	0.000951	CcSEcCtD
Rifabutin—Rash—Docetaxel—skin cancer	0.000171	0.000943	CcSEcCtD
Rifabutin—Dermatitis—Docetaxel—skin cancer	0.000171	0.000942	CcSEcCtD
Rifabutin—Headache—Docetaxel—skin cancer	0.00017	0.000937	CcSEcCtD
Rifabutin—HSP90B1—Innate Immune System—KRAS—skin cancer	0.000165	0.00179	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling by EGFR in Cancer—KRAS—skin cancer	0.000163	0.00177	CbGpPWpGaD
Rifabutin—Nausea—Docetaxel—skin cancer	0.000161	0.000888	CcSEcCtD
Rifabutin—HSP90AA1—Cell Cycle, Mitotic—CDK4—skin cancer	0.000158	0.00171	CbGpPWpGaD
Rifabutin—HSP90AA1—Cell Cycle—TERT—skin cancer	0.000158	0.00171	CbGpPWpGaD
Rifabutin—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—skin cancer	0.000153	0.00166	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling Pathways—GLI2—skin cancer	0.000153	0.00166	CbGpPWpGaD
Rifabutin—HSP90AA1—Developmental Biology—CDK4—skin cancer	0.000153	0.00165	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling by ERBB2—HRAS—skin cancer	0.000151	0.00163	CbGpPWpGaD
Rifabutin—HSP90AA1—Disease—SHH—skin cancer	0.000149	0.00161	CbGpPWpGaD
Rifabutin—HSP90AA1—Disease—ENO2—skin cancer	0.000149	0.00161	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling Pathways—MC1R—skin cancer	0.000146	0.00158	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling by ERBB2—IL6—skin cancer	0.000144	0.00156	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling Pathways—GLI1—skin cancer	0.000144	0.00156	CbGpPWpGaD
Rifabutin—CYP1A2—Arachidonic acid metabolism—PTGS2—skin cancer	0.000143	0.00155	CbGpPWpGaD
Rifabutin—HSP90AA1—Cell Cycle—CDK4—skin cancer	0.000141	0.00153	CbGpPWpGaD
Rifabutin—HSP90B1—Innate Immune System—HRAS—skin cancer	0.00014	0.00152	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling by EGFR in Cancer—HRAS—skin cancer	0.000139	0.0015	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling Pathways—SUFU—skin cancer	0.000136	0.00148	CbGpPWpGaD
Rifabutin—HSP90B1—Innate Immune System—IL6—skin cancer	0.000134	0.00146	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling by EGFR in Cancer—IL6—skin cancer	0.000133	0.00144	CbGpPWpGaD
Rifabutin—HSP90AA1—Immune System—FOXO4—skin cancer	0.000131	0.00142	CbGpPWpGaD
Rifabutin—HSP90AA1—Metabolism—ENO2—skin cancer	0.000124	0.00135	CbGpPWpGaD
Rifabutin—HSP90AA1—Disease—FOXO4—skin cancer	0.000121	0.00131	CbGpPWpGaD
Rifabutin—HSP90AA1—Cell Cycle, Mitotic—CDKN2A—skin cancer	0.000121	0.00131	CbGpPWpGaD
Rifabutin—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—skin cancer	0.000119	0.00129	CbGpPWpGaD
Rifabutin—HSP90AA1—Axon guidance—NRAS—skin cancer	0.000119	0.00129	CbGpPWpGaD
Rifabutin—HSP90B1—Immune System—NRAS—skin cancer	0.000112	0.00121	CbGpPWpGaD
Rifabutin—HSP90AA1—Cell Cycle—CDKN2A—skin cancer	0.000108	0.00117	CbGpPWpGaD
Rifabutin—CYP1A2—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	0.000107	0.00116	CbGpPWpGaD
Rifabutin—HSP90AA1—Cellular responses to stress—TP53—skin cancer	0.000107	0.00116	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling Pathways—SHH—skin cancer	0.000104	0.00113	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling Pathways—RASA1—skin cancer	0.000103	0.00112	CbGpPWpGaD
Rifabutin—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—skin cancer	0.000103	0.00111	CbGpPWpGaD
Rifabutin—HSP90AA1—Axon guidance—KRAS—skin cancer	0.000102	0.00111	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling Pathways—SMO—skin cancer	9.87e-05	0.00107	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling Pathways—PTCH1—skin cancer	9.87e-05	0.00107	CbGpPWpGaD
Rifabutin—HSP90AA1—Cellular responses to stress—IL6—skin cancer	9.8e-05	0.00106	CbGpPWpGaD
Rifabutin—HSP90B1—Immune System—KRAS—skin cancer	9.62e-05	0.00104	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling Pathways—PTGER4—skin cancer	9.61e-05	0.00104	CbGpPWpGaD
Rifabutin—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—skin cancer	8.72e-05	0.000946	CbGpPWpGaD
Rifabutin—HSP90AA1—Axon guidance—HRAS—skin cancer	8.69e-05	0.000943	CbGpPWpGaD
Rifabutin—HSP90AA1—Disease—ERCC2—skin cancer	8.63e-05	0.000937	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling Pathways—FOXO4—skin cancer	8.48e-05	0.00092	CbGpPWpGaD
Rifabutin—HSP90AA1—Developmental Biology—NRAS—skin cancer	8.48e-05	0.00092	CbGpPWpGaD
Rifabutin—HSP90AA1—Axon guidance—IL6—skin cancer	8.32e-05	0.000903	CbGpPWpGaD
Rifabutin—HSP90B1—Immune System—HRAS—skin cancer	8.17e-05	0.000887	CbGpPWpGaD
Rifabutin—HSP90AA1—Disease—TERT—skin cancer	8.09e-05	0.000878	CbGpPWpGaD
Rifabutin—HSP90B1—Immune System—IL6—skin cancer	7.82e-05	0.000849	CbGpPWpGaD
Rifabutin—HSP90AA1—Innate Immune System—NRAS—skin cancer	7.49e-05	0.000813	CbGpPWpGaD
Rifabutin—HSP90AA1—Developmental Biology—KRAS—skin cancer	7.3e-05	0.000792	CbGpPWpGaD
Rifabutin—HSP90AA1—Metabolism—ERCC2—skin cancer	7.23e-05	0.000784	CbGpPWpGaD
Rifabutin—HSP90AA1—Innate Immune System—KRAS—skin cancer	6.45e-05	0.000699	CbGpPWpGaD
Rifabutin—HSP90AA1—Disease—BRAF—skin cancer	6.41e-05	0.000695	CbGpPWpGaD
Rifabutin—HSP90AA1—Developmental Biology—HRAS—skin cancer	6.2e-05	0.000673	CbGpPWpGaD
Rifabutin—HSP90AA1—Cell Cycle—TP53—skin cancer	6.01e-05	0.000652	CbGpPWpGaD
Rifabutin—HSP90AA1—Developmental Biology—IL6—skin cancer	5.94e-05	0.000644	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling Pathways—TERT—skin cancer	5.67e-05	0.000615	CbGpPWpGaD
Rifabutin—HSP90AA1—Innate Immune System—HRAS—skin cancer	5.48e-05	0.000594	CbGpPWpGaD
Rifabutin—HSP90AA1—Innate Immune System—IL6—skin cancer	5.24e-05	0.000569	CbGpPWpGaD
Rifabutin—HSP90AA1—Disease—PTGS2—skin cancer	5.18e-05	0.000562	CbGpPWpGaD
Rifabutin—CYP1A2—Metabolism—PLIN2—skin cancer	4.78e-05	0.000518	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling Pathways—BRAF—skin cancer	4.49e-05	0.000487	CbGpPWpGaD
Rifabutin—HSP90AA1—Immune System—NRAS—skin cancer	4.36e-05	0.000473	CbGpPWpGaD
Rifabutin—HSP90AA1—Metabolism—PTGS2—skin cancer	4.34e-05	0.00047	CbGpPWpGaD
Rifabutin—HSP90AA1—Disease—NRAS—skin cancer	4.03e-05	0.000437	CbGpPWpGaD
Rifabutin—CYP1A2—Metabolism—CSPG4—skin cancer	3.85e-05	0.000418	CbGpPWpGaD
Rifabutin—HSP90AA1—Immune System—KRAS—skin cancer	3.75e-05	0.000407	CbGpPWpGaD
Rifabutin—CYP3A4—Metabolism—PLIN2—skin cancer	3.69e-05	0.0004	CbGpPWpGaD
Rifabutin—HSP90AA1—Disease—KRAS—skin cancer	3.47e-05	0.000376	CbGpPWpGaD
Rifabutin—HSP90AA1—Immune System—HRAS—skin cancer	3.19e-05	0.000346	CbGpPWpGaD
Rifabutin—HSP90AA1—Immune System—IL6—skin cancer	3.05e-05	0.000331	CbGpPWpGaD
Rifabutin—CYP3A4—Metabolism—CSPG4—skin cancer	2.97e-05	0.000322	CbGpPWpGaD
Rifabutin—HSP90AA1—Disease—HRAS—skin cancer	2.95e-05	0.00032	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling Pathways—NRAS—skin cancer	2.82e-05	0.000306	CbGpPWpGaD
Rifabutin—HSP90AA1—Disease—IL6—skin cancer	2.82e-05	0.000306	CbGpPWpGaD
Rifabutin—CYP1A2—Metabolism—ENO2—skin cancer	2.62e-05	0.000284	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling Pathways—KRAS—skin cancer	2.43e-05	0.000263	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling Pathways—TP53—skin cancer	2.16e-05	0.000234	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling Pathways—HRAS—skin cancer	2.06e-05	0.000224	CbGpPWpGaD
Rifabutin—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	2.05e-05	0.000222	CbGpPWpGaD
Rifabutin—CYP3A4—Metabolism—ENO2—skin cancer	2.02e-05	0.000219	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling Pathways—IL6—skin cancer	1.97e-05	0.000214	CbGpPWpGaD
Rifabutin—CYP1A2—Metabolism—ERCC2—skin cancer	1.52e-05	0.000165	CbGpPWpGaD
Rifabutin—CYP3A4—Metabolism—ERCC2—skin cancer	1.17e-05	0.000127	CbGpPWpGaD
Rifabutin—CYP1A2—Metabolism—PTGS2—skin cancer	9.12e-06	9.89e-05	CbGpPWpGaD
Rifabutin—CYP3A4—Metabolism—PTGS2—skin cancer	7.04e-06	7.63e-05	CbGpPWpGaD
